New York-based private equity firm, CCMP Capital Advisors, will acquire an 80% stake in Ohio-based clinical research organization, Medpace. The deal, which is likely to be valued at around $500 million, will see Medpace’s management team take the remaining 20% stake, adds AltAssets.
Medpace, which offers clinical trial services for drug, biologic and device programmes, expects to finalize the deal next month. August Troendle will remain as the president and CEO and the current management team will remain in place.
Click here for the release from Market Wire.
Click here for additional coverage from AltAssets.